Vet­er­an amy­loid cham­pi­on helps Alzheimer's start­up grab $160M in IPO as in­vestors charge back in to a once fad­ed field

The amy­loid be­ta the­o­ry in Alzheimer’s re­search has staged a come­back with in­vestors as well as the FDA.

Thurs­day morn­ing Acu­men Phar­ma­ceu­ti­cals priced its up­sized IPO at $16, hit­ting the high end of the range and scor­ing $160 mil­lion for the biotech.

Acu­men pitched in­vestors on the idea that the biotech of­fers a dif­fer­en­ti­at­ed ap­proach to amy­loid, tar­get­ing sol­u­ble amy­loid-be­ta oligomers, or AbOs, with its lead can­di­date ACU193.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER